干细胞移植可治疗II型糖尿病（附原文）

qing6628

3 o- K+ |7 y! y& r$ u  H2 t

/ n" o7 [$ @( ~- sStem Cell Reports：干细胞移植可治疗II型糖尿病
5 f4 `& w8 s; _$ @/ }) d来源：生物谷 2015-03-22 10:32
. ~% M9 \( z% d3 p; Y$ ^% O  
6 I+ U7 T- A8 ]: c2015年3月22日讯 /生物谷BIOON/ --近日，来自加拿大的科学家在国际期刊Stem Cell Reports在线发表了他们的最新研究成果，他们发现胰腺前体细胞移植对于II型糖尿病治疗具有良好效果，与糖尿病治疗药物联合使用，治疗效果更加明显，这项研究表明基于干细胞技术的治疗方法或许是治疗II型糖尿病的一种可行方法。) i" K, h1 a" D% `

0 s' F2 _) o/ r: @; n* Y人类胚胎干细胞诱导的胰腺前体细胞能够有效逆转I型糖尿病动物模型的高血糖症，但其对于II型糖尿病的治疗作用仍未有报道。研究人员通过高脂喂养SCID-beige小鼠构建了患有II型糖尿病的免疫缺陷模型，研究发现在进行干细胞移植后，高脂饮食刺激不会影响胰腺前体细胞向具有胰岛素分泌功能的胰腺细胞的分化成熟过程，并且这种细胞治疗方法能够改善接受了干细胞移植的小鼠在高脂饮食喂养下的葡萄糖耐受性，但其治疗效应要在干细胞移植24周后才会显现。. m3 ^4 Q! d! a# Y3 z# F
1 u$ Y! C& B4 i9 |% w* ^1 E
单纯依靠干细胞移植并不能完全改善饮食诱导的高血糖症和肥胖，因此研究人员对另一批II型糖尿病小鼠模型进行了胰腺前体细胞移植和糖尿病治疗药物的联合治疗，实验结果表明，选取的三种糖尿病治疗药物结合干细胞移植均能快速改善小鼠体重，并且干细胞移植与西格列汀或二甲双胍联用在移植后12周就可改善小鼠高血糖症。
+ {% b6 }5 d  O$ o( C0 V 4 K" X) |- W1 I
这项研究表明基于干细胞技术的治疗方法或许是治疗糖尿病的一种有效选择，与糖尿病治疗药物联用会起到更好的治疗效果。（生物谷Bioon.com）/ n( o' O7 z' Y2 `- [6 h7 K

2 ^: Z4 i1 d$ r2 `9 U0 F本文系生物谷原创编译整理。欢迎转载！转载请注明来源并附原文链接。更多资讯请下载生物谷资讯APP。3 F+ A4 U% v2 q1 q6 J3 O
& P9 m& e. }8 A

2 W: y5 i( A2 D1 ]7 q  J' `7 i% n' r
( B2 q/ |# U5 _7 b5 H6 U2 M& `DOI: http://dx.doi.org/10.1016/j.stemcr.2015.02.011
/ Q% }, u0 X0 m; e! w0 l- L, y
6 I' m7 O) l$ h* [0 bTreating Diet-Induced Diabetes and Obesity with Human Embryonic Stem Cell-Derived Pancreatic Progenitor Cells and Antidiabetic Drugs
2 I( x, X& y; ]5 }4 \. ?# N 6 e& g2 U; g9 b* P1 j
Jennifer E. Bruin, Nelly Saber, Natalie Braun, Jessica K. Fox, Majid Mojibian, Ali Asadi, Campbell Drohan, Shannon O'Dwyer, Diana S. Rosman-Balzer, Victoria A. Swiss, Alireza Rezania, Timothy J. Kieffer
7 G4 Y+ H6 O  ]4 p4 _9 ]' D8 t
9 T  V9 v- H. U; l5 MHuman embryonic stem cell (hESC)-derived pancreatic progenitor cells effectively reverse hyperglycemia in rodent models of type 1 diabetes, but their capacity to treat type 2 diabetes has not been reported. An immunodeficient model of type 2 diabetes was generated by high-fat diet (HFD) feeding in SCID-beige mice. Exposure to HFDs did not impact the maturation of macroencapsulated pancreatic progenitor cells into glucose-responsive insulin-secreting cells following transplantation, and the cell therapy improved glucose tolerance in HFD-fed transplant recipients after 24 weeks. However, since diet-induced hyperglycemia and obesity were not fully ameliorated by transplantation alone, a second cohort of HFD-fed mice was treated with pancreatic progenitor cells combined with one of three antidiabetic drugs. All combination therapies rapidly improved body weight and co-treatment with either sitagliptin or metformin improved hyperglycemia after only 12 weeks. Therefore, a stem cell-based therapy may be effective for treating type 2 diabetes, particularly in combination with antidiabetic drugs.
, k' ^2 E/ b. `' V( Z% p% M" R$ C0 h) {) E7 o6 I$ ?
" F/ p* V" C- }( Q8 ?( P
2楼原文 感谢Damon-Salvatore 提供; s( Q+ h4 p( b0 J0 {7 W7 c

Damon-Salvatore